Trinity Biotech says clinical trial data show CGM+ detects nocturnal false low glucose readings
PUBT · 2d ago
Share
Listen to the news
- Trinity Biotech released pre-pivotal clinical trial results for its CGM+ wearable, based on about 5,000 hours of wear data.
- Data supports an algorithm that flags nocturnal compression-related false low glucose readings, a common source of inaccurate CGM alarms.
- Management positioned the capability as a differentiator as CGM+ moves toward a pivotal trial and regulatory submission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020830PRIMZONEFULLFEED9756151) on July 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved